274 related articles for article (PubMed ID: 10225451)
1. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Grebenschikov N; Sweep F; Geurts A; Andreasen P; De Witte H; Schousboe S; Heuvel J; Benraad T
Int J Cancer; 1999 May; 81(4):598-606. PubMed ID: 10225451
[TBL] [Abstract][Full Text] [Related]
2. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Grebenschikov N; Geurts-Moespot A; De Witte H; Heuvel J; Leake R; Sweep F; Benraad T
Int J Biol Markers; 1997; 12(1):6-14. PubMed ID: 9176711
[TBL] [Abstract][Full Text] [Related]
3. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
[TBL] [Abstract][Full Text] [Related]
4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
[TBL] [Abstract][Full Text] [Related]
5. The imbalance of plasminogen activators and inhibitor in preeclampsia.
Gao M; Nakabayashi M; Sakura M; Takeda Y
J Obstet Gynaecol Res; 1996 Feb; 22(1):9-16. PubMed ID: 8624901
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
[TBL] [Abstract][Full Text] [Related]
7. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
Pedersen AN; Høyer-Hansen G; Brünner N; Clark GM; Larsen B; Poulsen HS; Danø K; Stephens RW
J Immunol Methods; 1997 Apr; 203(1):55-65. PubMed ID: 9134030
[TBL] [Abstract][Full Text] [Related]
8. [Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases].
Kushlinskiĭ NE; Gershteĭn ES; Kazantseva IA; Kharitidi TIu; Liakina LT; Kazakov SP; Bagatyrev OP; Kalinin AP
Vestn Ross Akad Med Nauk; 2001; (5):32-4. PubMed ID: 11510147
[TBL] [Abstract][Full Text] [Related]
9. Expression of the plasminogen activator system in the human vascular wall.
Salame MY; Samani NJ; Masood I; deBono DP
Atherosclerosis; 2000 Sep; 152(1):19-28. PubMed ID: 10996335
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Baker EA; Bergin FG; Leaper DJ
Mol Pathol; 2000 Dec; 53(6):307-12. PubMed ID: 11193049
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.
de Witte JH; Sweep CG; Klijn JG; Grebenschikov N; Peters HA; Look MP; van Tienoven TH; Heuvel JJ; van Putten WL; Benraad TJ; Foekens JA
Br J Cancer; 1999 Mar; 79(7-8):1190-8. PubMed ID: 10098758
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
15. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
16. Effects of thrombin on steroid-modulated cultured endometrial stromal cell fibrinolytic potential.
Lockwood CJ; Krikun G; Aigner S; Schatz F
J Clin Endocrinol Metab; 1996 Jan; 81(1):107-12. PubMed ID: 8550736
[TBL] [Abstract][Full Text] [Related]
17. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
18. Enzyme-linked immunosorbent assays for plasminogen activators.
Buessecker F; Reinartz J; Schirmer U; Kramer MD
J Immunol Methods; 1993 Jun; 162(2):193-200. PubMed ID: 8315289
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
20. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Levenson AS; Kwaan HC; Svoboda KM; Weiss IM; Sakurai S; Jordan VC
Br J Cancer; 1998 Jul; 78(1):88-95. PubMed ID: 9662256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
